LifeLines by Biocom California

Decades ago, the terms “artificial intelligence” and “machine learning” were associated with rogue robots and nefarious computers in sci-fi books and movies. Today, these technologies are a part of our everyday lives and as innocuous as predictive text appearing in a messaging app, a robot on wheels delivering food to your table at a restaurant, or a student using Chat GPT for writing prompts. But what applications does AI, big data, and machine learning have in life science?  

On this week’s episode of LifeLines, our final episode of Season 1, we chat with Peyton Greenside, Ph.D., co-founder and CSO of BigHat Biosciences—and how her company harnesses the power of AI and machine learning to discover and engineer antibodies to accelerate the development of next-gen drug therapies for infectious diseases, oncology and inflammation. A previous Catalyst Awards winner and a pioneer of deep learning applied to life science problems, Peyton also shares the challenges that come with working with this unique technology and what it could mean for the future of drug discovery. 

BigHat was founded in San Mateo in 2019 and has since forged partnerships with big names in life science—Amgen, Merck, Bristol Myers Squibb—for its AI-guided antibody design platform. BigHat describes their technology as integrating a high-speed wet lab with machine learning to drive the search for better antibodies, at a much faster rate than current technologies allow. Peyton says the platform can address existing limitations in molecular design by substantially shortening lab-cycle times for experiments and enabling increasingly sophisticated designs to address diseases with significant unmet need. 

“It’s really, in short summary, to close the loop as quickly as possible between the lab and the computational side to be able to iterate quite rapidly and develop novel antibodies for addressing these diseases,” Peyton explains. “The goal of the company was actually to realize the potential of machine learning in life sciences—where I think there's been a ton of excitement—and I think we're still at the early days of ‘how are the impacts actually being realized from the potential of this technology?’” 

Although BigHat is taking a futuristic approach to drug discovery, Peyton says we can’t forget about the human element and connection needed within life science companies to unlock technology’s potential. She and BigHat Co-Founder Mark DePristo launched the company just one year before the pandemic lockdown, and navigated maintaining a positive company culture and camaraderie among staff when everyone couldn’t physically be together at the lab. Learn more about Peyton Greenside and BigHat Biosciences.  

This concludes Season 1 of the LifeLines podcast! Thank you for joining us on this journey into the stories behind the life science innovation happening in California.

LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit biocom.org or engage with us on Twitter and LinkedIn. For a transcript of this episode, you can download it here. Interested in becoming a member or learning more about this podcast? Email [email protected]. 

Host: Chris Conner 
Executive Producer: Marie Tutko 
Senior Producer: Vincenzo Tarantino 
Associate Producer: Lauren Panetta 
Program & Research Coordinator: Katy Burgess 
Transcripts By: Jessica Schneider  
Senior Director of Marketing: Heather Ramsay 
Graphic Design By: Raquel Papike 

Mention Orange County to the average person and images of Disneyland, Laguna Beach and high-end shopping malls may come to mind. Life science industry insiders know that beyond the county’s famous landmarks is a nascent biotechnology hub—more than 63,000 people there were employed by the sector last year, and the number of startups establishing roots in Orange County is growing. In 2020, biotech startups gained a new place to set up shop when University Lab Partners, the first wet lab incubator for biotech and medtech companies in the region, opened near the University of California, Irvine campus. Karin Koch, its executive director, calls it “the Four Seasons of incubators” and says it has helped 70 companies since opening. 

Karin says University Lab Partners’ approach—which was founded in partnership with UC Irvine’s Beall Applied Innovation—is an “all-inclusive concierge model” where startups receive support services in addition to access to labs: event planning, business counseling, networking, and finding a venue when they’re ready to graduate. For Karin, directing an incubator goes far beyond collecting rent—it’s about offering startup founders a sense of community and helping them on their journey. Having been one of the few women in an electrical engineering class while in college, she knows first-hand what it’s like to feel isolated. “Being a CEO or owner of a company, it's a very lonely place. Not a lot of people can relate to you,” she says. This is where incubators like University Lab Partners come in—they can connect founders with like-minded people who can serve as a sounding board and co-collaborator. “Part of the reason why I'm so impassioned about the work is so that women and underrepresented minorities in STEM really have this safe social network…ULP is focused on life sciences and there are severe disparities in STEM (and especially the life sciences) that we need to highly focus our efforts there.” 

Today, University Lab Partners has a second location in Aliso Viejo and houses a total of 42 companies that will hopefully stay in Orange County when they outgrow the incubator, as many previous tenants have. We hear more from Karin about the larger role (and responsibility) incubators play in a city’s economic development and the diversity of the STEM workforce, University Lab Partners’ involvement with an outreach program for high school students, and how a company’s graduation day can feel like a parent sending their child off to college. 

Learn more about Karin Koch and University Lab Partners. 

LifeLines  is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit biocom.org or engage with us on Twitter and LinkedIn. For a transcript of this episode, you can download it here. Interested in becoming a member or joining us on this podcast? Email [email protected]. 

Host: Bob McGriff 
Executive Producer: Marie Tutko 
Senior Producer: Vincenzo Tarantino 
Associate Producer: Lauren Panetta 
Program & Research Coordinator: Katy Burgess 
Transcripts By: Jessica Schneider  
Senior Director of Marketing: Heather Ramsay 
Graphic Design By: Raquel Papike 

The San Francisco Bay Area is known as the “birthplace of biotech” and a center of the tech world, but did you know the local biomedical industry—companies developing new drugs and foods, medical devices and equipment, digital healthcare, and more—number in the thousands in the region? And that where a life science company first sets up shop in the Bay Area can indicate where it may move to in the future? 

Gregory Theyel, Ph.D., a biomedical engineer and professor at California State University East Bay, discovered this ten years ago when he first sought out startups to help through the nonprofit Biomedical Manufacturing Network—an organization collectively started by UC Berkeley, Manex, and government entities to support the local biomedical ecosystem and provide companies with roadmaps to success—where he serves as program director. He wanted to find out where these companies were located in the Bay Area, but a comprehensive database with this information didn’t exist. A self-professed “map guy,” Gregory collected the data and built a heat map plotting each biomedical manufacturing company in the region from the ground up. The Biomedical Manufacturing Network, which originated from grant support, studies and shares this data: about 1,000 companies were identified when they first began. Today, there are 2,500. 

How can all this information in the network be used? Through this project, Gregory identified three economic “microclimates” in the Bay Area and spotted relocation trends as companies grow and need funding, which enables him to assist with location strategy. Various businesses and entities are wanting this data, too: realtors can forecast which companies need more space; service providers, lawyers, and contract research organizations can find potential customers; and government agencies and nonprofits can locate companies that need funding. The network’s long-term goal is to facilitate the transfer of manufacturing technology between labs, universities and companies, and keep the infrastructure for a biomedical manufacturing ecosystem in the Bay Area.  

We hear more from Gregory about how the Biomedical Manufacturing Network can assist startups and what kind of companies they are looking for, learn about the Tech Futures Group—another association he belongs to which helps startups find resources, capital and more—the latest technologies he’s excited about, and why he was a pioneer in online teaching. 

Learn more about the Biomedical Manufacturing Network.  

LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit biocom.org or engage with us on Twitter and LinkedIn. For a transcript of this episode, you can download it here. Interested in becoming a member or joining us on this podcast? Email [email protected]. 

Host: Chris Conner  
Executive Producer: Marie Tutko 
Senior Producer: Vincenzo Tarantino 
Associate Producer: Lauren Panetta 
Program & Research Coordinator: Katy Burgess 
Transcripts By: Jessica Schneider  
Senior Director of Marketing: Heather Ramsay 
Graphic Design By: Raquel Papike 

How does a biotech startup manage to forge $125 million in partnerships with AbbVie and Eli Lilly in just under two years post-inception? Our next guest, Peter Anastasiou, CEO of Capsida Biotherapeutics since 2022, attributes much of the company's rise to addressing unmet patient needs. First invented by Viviana Gradinaru, director of the Center for Molecular and Cellular Neuroscience at the Chen Institute for Neuroscience at the California Institute of Technology, Capsida’s next-generation gene therapy platform engineers the capsids in adeno-associated viruses, or AAVs. The company uses this technology to develop treatments that are being researched for central nervous system and eye disorders. 

A key principle of life science success is embracing a diverse leadership team, and Peter is a longtime advocate of gender parity at the leadership level and has been honored for his mentoring contributions—he was named the Honorable Mentor by the Healthcare Businesswomen’s Association in 2019. His dedication to mentoring women is not only personally important to him as a father of two daughters, he says it makes the most business sense in addition to being the right thing to do. “The idea of trying to conquer such daunting challenges that we do in biotech…with a basically homogeneous group of people trying to solve that problem…it's never going to happen,” he says. “The only way to solve the challenges is by bringing the best minds around the table.”

Learn more about Capsida Biotherapeutics and Peter Anastasiou.

LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit biocom.org or

Host: Chris Conner
Executive Producer: Marie Tutko
Senior Producer: Vincenzo Tarantino
Associate Producer: Lauren Panetta
Program & Research Coordinator: Katy Burgess
Transcripts By: Jessica Schneider
Senior Director of Marketing: Heather Ramsay
Graphic Design By: Raquel Papike

Kit Pogliano says her colleagues from graduate school would have voted her the least likely person from class to go into university administration, let alone become a dean of an entire school. But after building a 20-year career as a professor, researcher, and leader at University of California, San Diego, she became the first female Dean of the School of Biological Sciences—which U.S. News & World Report ranks as No. 7 in the world for its biology and biochemistry programs—in 2018. 

Kit’s research focuses on how bacteria cells are organized, grow, and interact with antibiotics and ways to harness their molecules to develop new therapies. She’s not only passionate about studying the ins and outs of how these tiny microorganisms operate, but how the broad ecosystem of the life science industry in her community thrives. She says higher education institutions play a bigger role beyond advancing science: they drive regional economic development and social advancement, and are an engine for developing a creative life science industry.   

On this episode, we learn how UC San Diego is cultivating a diverse group of future scientists and researchers. It’s partnered with private companies—such as Illumina and Thermo Fisher Scientific—to provide students with applicable job training, as well as give professionals access to the latest cutting-edge scientific equipment. The recent launch of the Goeddel Family Technology Sandbox, a new facility on campus, is an example of this goal of creating pathways to careers and opportunities coming to life, as well as a federally funded community project to build training modules and boot camp programs. 

We dive more into Kit’s research and how her biotechnology company, Linnaeus Bioscience, is working with the Gates Foundation and the Tuberculosis Alliance on mode of action studies on newly discovered anti-tuberculosis drugs. She co-founded the company with her husband, Joe, and attributes their “extreme partnership” to her career and academic success. Kit shares why she believes strongly in a “people-first” leadership style, and how overcoming a family illness early in her career shaped this philosophy.  

Learn more about Kit Pogliano’s research and lab. For information on UC San Diego’s School of Biological Sciences, visit their website. 

LifeLines  is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit biocom.org or engage with us on Twitter and LinkedIn. For a transcript of this episode, you can download it here. Interested in becoming a member or joining us on this podcast? Email [email protected]. 

Host: Bob McGriff  
Executive Producer: Marie Tutko 
Senior Producer: Vincenzo Tarantino 
Associate Producer: Lauren Panetta 
Program & Research Coordinator: Katy Burgess 
Transcripts By: Jessica Schneider  
Senior Director of Marketing: Heather Ramsay 
Graphic Design By: Raquel Papike 

What do Magic Johnson, the McGovern Medical School at UTHealth Houston, and a molecule have in common? They each played an unexpected role in changing the course of our next guest, Stanley Lewis, CEO and founder of San Diego-based A28 Therapeutics, on his path toward finding a novel treatment for cancer and advocating for patient diversity in clinical trials.

On this episode of LifeLines, Stanley speaks about his journey from academia to blazing his own trail in biotech and founding his own company. As a physician, Stanley specialized in treating HIV patients and helped lead the development of a new HIV drug for a large company. This got the attention of Magic Johnson’s doctor, who recruited him to join Tai Med Biologics. Stanley never imagined he would one day be a biotech founder: an interview for a CMO position at a company that was retooling a molecule to treat cancer led him to San Diego. This meeting resulted in him purchasing the rights to the asset instead, establishing A28 Therapeutics. Stanley says it was “off to the races” from that point. “There’s really no blueprint for what you're

A28 Therapeutics developed a targeted oncolytic peptide platform to treat multiple types of cancers, including ovarian cancer and hepatocellular carcinoma. A28 Therapeutics' lead compound, AT-101—which is in its Phase 2 clinical trial—could potentially kill cancer cells much like how a vaccine treats infectious diseases, Stanley says. The company’s goal is to find a treatment for cancer that doesn’t cause the side effects often experienced with chemotherapy.

Stanley is also passionate about advocating for patient diversity in clinical trials, and he shares the news about a nonprofit he co-founded, CARER, that monitors data on patient enrollment in clinical trials. CARER was born from an idea shared by a colleague who attended Biocom California’s inaugural Black Biotech Trailblazers panel, where Stanley was a guest speaker. She approached him after the event, and their discussion on addressing diversity issues in the

You can follow Stanley Lewis and A28 Therapeutics on LinkedIn.

LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit biocom.org

Host: Bob McGriff
Executive Producer: Marie Tutko
Senior Producer: Vincenzo Tarantino
Associate Producer: Lauren Panetta
Program & Research Coordinator: Katy Burgess
Transcripts By: Jessica Schneider
Senior Director of Marketing: Heather Ramsay
Graphic Design By: Raquel Papike

Women make up half of the globe’s population, but the dollars devoted to finding treatments for women’s unique health issues—beyond conditions such as breast cancer—are significantly underfunded. Only 1 percent of research dollars are invested in women's health concerns, and women's health represents only 2 percent of the development pipeline of preclinical products for non-cancer related conditions, according to a 2022 McKinsey & Company report. Sabrina Martucci Johnson, president and CEO of Daré Bioscience, says this is not congruent, at all, with the need and demand for such products and the fact that women account for 80 percent of consumer purchase decisions for healthcare.  

“A lot of the women's health indications are conditions that are simply just a part of being a woman. They're not life threatening, but they're life altering in many cases,” Sabrina says. This gender gap in product development motivated Sabrina to found Daré Bioscience (pronounced Dah-ray and meaning "to give" in Italian) in 2015, which is focused on finding novel treatments for women’s health issues—encompassing reproductive, vaginal, and sexual health—and bringing them to market.

In this episode of LifeLines—airing just before National Women’s Health Week—we delve more into these healthcare inequities and learn about how Daré is addressing these unmet health needs with its product pipeline. The company’s first FDA-approved product, Xaciato, came out in 2021, and Daré is in its Phase 3 clinical trial for a monthly hormone-free contraceptive, in collaboration with Bayer—the only company that's built an over billion-dollar contraceptive brand. It’s also in Phase 2 for its product Sildenafil, a treatment for female sexual arousal disorder.  

Sabrina shares the challenges of raising capital when you're one of the first in your field, despite having proof of concept, and how three mentors (and a chance encounter on an elevator) were instrumental in launching Daré.

LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit ⁠biocom.org⁠ or engage with us on ⁠Twitter⁠ and ⁠LinkedIn⁠. For a transcript of this episode, you can download it ⁠here.⁠ Interested in becoming a member or joining us on this podcast? Email ⁠[email protected]⁠. 

Host: Chris Conner

Executive Producer: Marie Tutko

Senior Producer: Vincenzo Tarantino

Associate Producer: Lauren Panetta

Program & Research Coordinator: Katy Burgess

Transcripts By: Jessica Schneider

Senior Director of Marketing: Heather Ramsay

Graphic Design By: Raquel Papike

Element Biosciences is on a mission to democratize next-generation sequencing by helping scientists overcome a major lack of diversity in genomic studies. A recent article in Nature Medicine cited that as of June 2021, 86 percent of genomics studies have been conducted in individuals of European decent, leaving researchers without adequate data representing our global population. The promise of genomic research equates to improving our understanding of disease etiology, early detection and diagnosis, drug design and clinical care. Without representation of all populations, we’re missing a big piece of the puzzle that allows the advancement of health for humanity. By reimagining DNA sequencing and lowering costs to make it more accessible, Element is removing these barriers and enabling new discoveries that have the potential to dramatically improve health outcomes around the world. 

Five years ago, Molly He met with two of her former Illumina colleagues at the UC San Diego library to create a company focused on making reagents for other sequencing companies. “And then we thought, ‘Why don’t we make our own platform?’” Molly explains how the group’s naivete was integral in this business pivot because they never could have imagined the challenges they’d encounter along the way.  

Molly was born and raised in China and came to UCLA for graduate school. She was unsure at the time if science would be her chosen career path, but she credits having a great mentor who taught her the mystery and excitement behind solving a scientific problem. At Element, her passion for health equity is what drives her and her team to bring sequencing to areas of the world that don’t have the means to buy expensive instruments. Increasing access to sequencing ultimately expands the library of genomic data available and benefits everyone. 

Element now offers an option for its AVITI System that provides high quality sequencing for $200 a genome and even lower volume-based pricing for customers with high throughput. On April 19, 2023, Element announced it had signed distribution agreements with companies based in Israel, South Korea, Australia, and the United Arab Emirates to help bring its AVITI System to more customers around the world.  

You can follow Molly He and Element Biosciences on LinkedIn. 

LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit biocom.org or engage with us on Twitter and LinkedIn. For a transcript of this episode, you can download it here. Interested in becoming a member or joining us on this podcast? Email [email protected]. 

 
Host: Chris Conner 
Executive Producer: Marie Tutko 
Senior Producer: Vincenzo Tarantino 
Associate Producer: Lauren Panetta 
Program & Research Coordinator: Katy Burgess 
Transcripts By: Jessica Schneider  
Senior Director of Marketing: Heather Ramsay 
Graphic Design By: Raquel Papike 

Karius’ story is all about equipping doctors with the right information, for the right patient, at the right time. For most immunocompromised patients, it’s a matter (quite literally) of life or death. 

When Alec Ford’s daughter was just a toddler, she suffered with asthma and caught a viral infection that led to secondary bacterial infections and was hospitalized multiple times. Alec says he watched doctors try to help his daughter, but the tools they had to figure out exactly how to provide the best anti-infective care for her were all a failure. “They couldn't find the cause, they'd get the antibiotic wrong. I held her hand as they put her to sleep through multiple bronchoscopies, which as a new parent, you can imagine, just terrifies you to no end,” Alec says. “That’s why I’m at this company. It was this chance to be a part of changing something that was very personal to me.”  

Alec, who graduated from Stanford University and has more than 30 years of experience at top biopharma companies, including Pfizer, Sanofi-Aventis, Novartis, Nektar Therapeutics, and Myriad Genetics, is now CEO of ⁠Karius⁠. Karius developed the trademarked ⁠Karius Test⁠, a non-invasive liquid biopsy that can identify more than ⁠1,500 pathogens⁠—including the monkeypox virus—and helps clinicians identify the source of an infection in an immunocompromised patient, such as people who have cancer. Alec says that out of the 630,000 or so cancer deaths that occur every year in the U.S., over half of them are actually due to infection.  

Karius recently raised $165 million from a Series B funding round and was recently named to the Forbes AI 50, a list of the most promising artificial intelligence companies. 

You can follow Alec Ford and Karius on ⁠LinkedIn⁠.

LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit ⁠biocom.org⁠ or engage with us on ⁠Twitter⁠ and ⁠LinkedIn⁠. For a transcript of this episode, you can download it ⁠here.⁠ Interested in becoming a member or joining us on this podcast? Email ⁠[email protected]⁠. 

Host: Chris Conner 

Executive Producer: Marie Tutko 

Senior Producer: Vincenzo Tarantino 

Associate Producer: Lauren Panetta 

Program & Research Coordinator: Katy Burgess 

Transcripts By: Jessica Schneider  

Senior Director of Marketing: Heather Ramsay 

Graphic Design By: Raquel Papike 

Biocom California’s new podcast, LifeLines, brings you direct access to leaders in the life science industry for candid one-on-one conversations about the journeys they’ve taken, both professionally and personally, toward bettering human and environmental health. Biocom California is a member and advocacy organization that accelerates life science success in California and beyond. With over 1,700 companies in our network, we hear inspiring stories every day about founders who beat the odds and the relentless pursuit to improving the human condition. We are so proud to share these stories of success, determination, and innovation with the world.

In this first season of LifeLines, we interview guests who are researching new treatments for cancer, developing life-saving drugs, and using artificial intelligence to discover new medicines. We speak with first-time founders, a CEO whose company invented a test that can detect over 1,500 pathogens, and leaders advocating for diversity in the industry, both in clinical trials and in our talent pipeline.

This season’s guests include: 

LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit biocom.org or engage with us on ⁠Twitter⁠ and ⁠LinkedIn⁠. Interested in becoming a member or joining us on this podcast? Email us at ⁠[email protected]⁠. 

Hosts: Bob McGriff; Chris Conner 

Executive Producer: Marie Tutko 

Senior Producer: Vincenzo Tarantino 

Associate Producer: Lauren Panetta 

Program & Research Coordinator: Katy Burgess 

Transcripts By: Jessica Schneider  

Senior Director of Marketing: Heather Ramsay 

Graphic Design By: Raquel Papike